Phase I clinical and pharmacological study of liposome-entrapped cis-Bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II)

Roman Perez-Soler, Gabriel Lopez-Berestein, Julio Lautersztain, Salam Al-Baker, Karen Francis, Dede Macias-Kiger, Martin N. Raber, Abdul R. Khokhar

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

cis-Bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) (NDDP) is a liposome dependent cisplatin analogue since the liposome carrier is required for its i.v. administration and for its biological activity. A Phase I study of liposome entrapped NDDP (L-NDDP) was performed using a single i.v. injection every 4 weeks. L-NDDP was prepared and characterized at M. D. Anderson Cancer Center. The maximum tolerated dose of L-NDDP was 312.5 mg/m2. The dose-limiting toxicity was myelosuppression, affecting all three blood cell lineages. The granulocyte nadir occurred on days 14-18, and the platelet nadir consistently earlier (days 11-12). The median day of recovery of blood cell counts was day 21 (range, 18-32). Other toxicities included grade 2 nausea and vomiting, fever consisting of a single temperature spike in most patients, grade 1 diarrhea after 60% of courses, and grade 1-2 malaise lasting for 5-10 days after the infusion in 73% of courses. Transient alanine aminotransferase elevations without clinical relevance were common. No signs of renal dysfunction or ototoxicity were observed. One patient with a preexisting peripheral neuropathy showed some progression of the neuropathy after a cumulative dose of 1605 mg/m2. Except for fever and transient liver dysfunction, no liposome related side effects were observed in spite of the high doses of lipid administered. The blood clearance of L-NDDP fits a two-compartment model at lower doses and a single-compartment model at the maximum tolerated dose, suggesting that saturation of the reticuloendothelial organs occurs at the maximum tolerated dose. Two minimal responses were observed. L-NDDP has a toxicity profile similar to that of carboplatin. Phase II studies to address the issue of how the therapeutic index of platinum compounds is affected by liposome entrapment are being planned.

Original languageEnglish (US)
Pages (from-to)4254-4259
Number of pages6
JournalCancer Research
Volume50
Issue number14
StatePublished - Jul 15 1990
Externally publishedYes

Fingerprint

Liposomes
Pharmacology
Maximum Tolerated Dose
Fever
Platinum Compounds
((1R,2R)-1,2-diaminocyclohexane)platinum(II)
Clinical Studies
Blood Cell Count
Carboplatin
Peripheral Nervous System Diseases
Cell Lineage
Alanine Transaminase
Granulocytes
Nausea
Cisplatin
Vomiting
Liver Diseases
Diarrhea
Blood Cells
Blood Platelets

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Perez-Soler, R., Lopez-Berestein, G., Lautersztain, J., Al-Baker, S., Francis, K., Macias-Kiger, D., ... Khokhar, A. R. (1990). Phase I clinical and pharmacological study of liposome-entrapped cis-Bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II). Cancer Research, 50(14), 4254-4259.

Phase I clinical and pharmacological study of liposome-entrapped cis-Bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II). / Perez-Soler, Roman; Lopez-Berestein, Gabriel; Lautersztain, Julio; Al-Baker, Salam; Francis, Karen; Macias-Kiger, Dede; Raber, Martin N.; Khokhar, Abdul R.

In: Cancer Research, Vol. 50, No. 14, 15.07.1990, p. 4254-4259.

Research output: Contribution to journalArticle

Perez-Soler, R, Lopez-Berestein, G, Lautersztain, J, Al-Baker, S, Francis, K, Macias-Kiger, D, Raber, MN & Khokhar, AR 1990, 'Phase I clinical and pharmacological study of liposome-entrapped cis-Bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II)', Cancer Research, vol. 50, no. 14, pp. 4254-4259.
Perez-Soler R, Lopez-Berestein G, Lautersztain J, Al-Baker S, Francis K, Macias-Kiger D et al. Phase I clinical and pharmacological study of liposome-entrapped cis-Bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II). Cancer Research. 1990 Jul 15;50(14):4254-4259.
Perez-Soler, Roman ; Lopez-Berestein, Gabriel ; Lautersztain, Julio ; Al-Baker, Salam ; Francis, Karen ; Macias-Kiger, Dede ; Raber, Martin N. ; Khokhar, Abdul R. / Phase I clinical and pharmacological study of liposome-entrapped cis-Bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II). In: Cancer Research. 1990 ; Vol. 50, No. 14. pp. 4254-4259.
@article{3a4aebdd0e854bcf966b1737e8ce124e,
title = "Phase I clinical and pharmacological study of liposome-entrapped cis-Bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II)",
abstract = "cis-Bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) (NDDP) is a liposome dependent cisplatin analogue since the liposome carrier is required for its i.v. administration and for its biological activity. A Phase I study of liposome entrapped NDDP (L-NDDP) was performed using a single i.v. injection every 4 weeks. L-NDDP was prepared and characterized at M. D. Anderson Cancer Center. The maximum tolerated dose of L-NDDP was 312.5 mg/m2. The dose-limiting toxicity was myelosuppression, affecting all three blood cell lineages. The granulocyte nadir occurred on days 14-18, and the platelet nadir consistently earlier (days 11-12). The median day of recovery of blood cell counts was day 21 (range, 18-32). Other toxicities included grade 2 nausea and vomiting, fever consisting of a single temperature spike in most patients, grade 1 diarrhea after 60{\%} of courses, and grade 1-2 malaise lasting for 5-10 days after the infusion in 73{\%} of courses. Transient alanine aminotransferase elevations without clinical relevance were common. No signs of renal dysfunction or ototoxicity were observed. One patient with a preexisting peripheral neuropathy showed some progression of the neuropathy after a cumulative dose of 1605 mg/m2. Except for fever and transient liver dysfunction, no liposome related side effects were observed in spite of the high doses of lipid administered. The blood clearance of L-NDDP fits a two-compartment model at lower doses and a single-compartment model at the maximum tolerated dose, suggesting that saturation of the reticuloendothelial organs occurs at the maximum tolerated dose. Two minimal responses were observed. L-NDDP has a toxicity profile similar to that of carboplatin. Phase II studies to address the issue of how the therapeutic index of platinum compounds is affected by liposome entrapment are being planned.",
author = "Roman Perez-Soler and Gabriel Lopez-Berestein and Julio Lautersztain and Salam Al-Baker and Karen Francis and Dede Macias-Kiger and Raber, {Martin N.} and Khokhar, {Abdul R.}",
year = "1990",
month = "7",
day = "15",
language = "English (US)",
volume = "50",
pages = "4254--4259",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "14",

}

TY - JOUR

T1 - Phase I clinical and pharmacological study of liposome-entrapped cis-Bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II)

AU - Perez-Soler, Roman

AU - Lopez-Berestein, Gabriel

AU - Lautersztain, Julio

AU - Al-Baker, Salam

AU - Francis, Karen

AU - Macias-Kiger, Dede

AU - Raber, Martin N.

AU - Khokhar, Abdul R.

PY - 1990/7/15

Y1 - 1990/7/15

N2 - cis-Bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) (NDDP) is a liposome dependent cisplatin analogue since the liposome carrier is required for its i.v. administration and for its biological activity. A Phase I study of liposome entrapped NDDP (L-NDDP) was performed using a single i.v. injection every 4 weeks. L-NDDP was prepared and characterized at M. D. Anderson Cancer Center. The maximum tolerated dose of L-NDDP was 312.5 mg/m2. The dose-limiting toxicity was myelosuppression, affecting all three blood cell lineages. The granulocyte nadir occurred on days 14-18, and the platelet nadir consistently earlier (days 11-12). The median day of recovery of blood cell counts was day 21 (range, 18-32). Other toxicities included grade 2 nausea and vomiting, fever consisting of a single temperature spike in most patients, grade 1 diarrhea after 60% of courses, and grade 1-2 malaise lasting for 5-10 days after the infusion in 73% of courses. Transient alanine aminotransferase elevations without clinical relevance were common. No signs of renal dysfunction or ototoxicity were observed. One patient with a preexisting peripheral neuropathy showed some progression of the neuropathy after a cumulative dose of 1605 mg/m2. Except for fever and transient liver dysfunction, no liposome related side effects were observed in spite of the high doses of lipid administered. The blood clearance of L-NDDP fits a two-compartment model at lower doses and a single-compartment model at the maximum tolerated dose, suggesting that saturation of the reticuloendothelial organs occurs at the maximum tolerated dose. Two minimal responses were observed. L-NDDP has a toxicity profile similar to that of carboplatin. Phase II studies to address the issue of how the therapeutic index of platinum compounds is affected by liposome entrapment are being planned.

AB - cis-Bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) (NDDP) is a liposome dependent cisplatin analogue since the liposome carrier is required for its i.v. administration and for its biological activity. A Phase I study of liposome entrapped NDDP (L-NDDP) was performed using a single i.v. injection every 4 weeks. L-NDDP was prepared and characterized at M. D. Anderson Cancer Center. The maximum tolerated dose of L-NDDP was 312.5 mg/m2. The dose-limiting toxicity was myelosuppression, affecting all three blood cell lineages. The granulocyte nadir occurred on days 14-18, and the platelet nadir consistently earlier (days 11-12). The median day of recovery of blood cell counts was day 21 (range, 18-32). Other toxicities included grade 2 nausea and vomiting, fever consisting of a single temperature spike in most patients, grade 1 diarrhea after 60% of courses, and grade 1-2 malaise lasting for 5-10 days after the infusion in 73% of courses. Transient alanine aminotransferase elevations without clinical relevance were common. No signs of renal dysfunction or ototoxicity were observed. One patient with a preexisting peripheral neuropathy showed some progression of the neuropathy after a cumulative dose of 1605 mg/m2. Except for fever and transient liver dysfunction, no liposome related side effects were observed in spite of the high doses of lipid administered. The blood clearance of L-NDDP fits a two-compartment model at lower doses and a single-compartment model at the maximum tolerated dose, suggesting that saturation of the reticuloendothelial organs occurs at the maximum tolerated dose. Two minimal responses were observed. L-NDDP has a toxicity profile similar to that of carboplatin. Phase II studies to address the issue of how the therapeutic index of platinum compounds is affected by liposome entrapment are being planned.

UR - http://www.scopus.com/inward/record.url?scp=0025307011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025307011&partnerID=8YFLogxK

M3 - Article

VL - 50

SP - 4254

EP - 4259

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 14

ER -